照亮生命孤岛

Core Viewpoint - The article highlights the efforts of Peking Union Medical College Hospital in addressing rare diseases through a multi-disciplinary approach, establishing a national network for diagnosis and treatment, and leveraging advanced technologies for better patient outcomes [2][8][15]. Group 1: Multi-disciplinary Collaboration - Peking Union Medical College Hospital has established a multi-disciplinary consultation model to tackle the complexities of rare diseases, bringing together experts from various fields to improve diagnosis and treatment [4][5]. - The hospital has created a national rare disease directory, listing 207 rare diseases, which serves as a foundation for standardized treatment guidelines and drug development [4][6]. - The hospital's weekly multi-disciplinary consultations have led to significant breakthroughs in diagnosing previously undiagnosed cases, showcasing the effectiveness of collaborative efforts [5][6]. Group 2: National Network and Training - A national rare disease diagnosis and treatment collaboration network has been established, covering 31 provinces and 624 medical institutions, facilitating better resource allocation and support for local hospitals [7][8]. - The average diagnosis time for rare diseases has been reduced from over 4 years to approximately 4 weeks, with annual treatment costs decreasing by about 90% [7][8]. - The hospital has trained over 151,000 medical personnel through a nationwide capacity-building project, enhancing the overall diagnostic capabilities for rare diseases [17]. Group 3: Technological Advancements - The "Xiehe·Taichu" AI model for rare diseases was launched, enabling doctors to input symptoms and receive potential diagnoses and recommended tests, significantly improving diagnostic efficiency [9][10]. - The hospital has made significant genetic discoveries, identifying 35 new pathogenic genes associated with rare diseases, which could lead to targeted therapies [9][10]. Group 4: Drug Accessibility and Development - Peking Union Medical College Hospital has implemented a "green channel" for the expedited approval and use of rare disease medications, facilitating quicker access to life-saving drugs for patients [10][11]. - The hospital has been instrumental in the approval of 134 rare disease treatments in China, with over 80 of these drugs included in the national health insurance directory, resulting in an average price reduction of over 50% [12][13]. - The hospital is actively involved in the development of new therapies for previously untreatable rare diseases, including gene editing trials [13][14]. Group 5: Future Sustainability and Knowledge Transfer - The hospital emphasizes the importance of training future medical professionals in rare disease diagnosis and treatment, having developed the first rare disease clinical guidelines and graduate courses in China [16][17]. - A national rare disease registry has been established, documenting over 100,000 patient cases, which enhances the scientific value and research capabilities in the field [17]. - The hospital's innovative practices have been recognized with awards, underscoring its contributions to the global understanding and management of rare diseases [17].